Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.41 |
| ▸ | ACE | P12821 | 6/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 3/20 | 0.38 |
| ▸ | NPY1R | P25929 | 2/20 | 0.38 |
| ▸ | NPY2R | P49146 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.38 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.38 |
| ▸ | CALCR | P30988 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29801999 | 0.93 | OPRM1 (0.48) | OPRM1OPRK1ACE | |
| SCHEMBL31593308 | 0.90 | OPRM1 (0.41) | OPRM1OPRK1ACEREN | |
| SCHEMBL29802056 | 0.89 | OPRK1 (0.46) | OPRM1OPRK1ACENPY4RNPY1R | |
| SCHEMBL29802258 | 0.88 | OPRM1 (0.52) | OPRM1OPRK1ACE | |
| SCHEMBL30471842 | 0.88 | ACE (0.41) | OPRM1OPRK1ACERENNPY4R | |
| SCHEMBL31593272 | 0.87 | PLK1 (0.38) | NPY4RNPY1RNPY2RNPY5RRAMP3 | |
| SCHEMBL31265332 | 0.87 | ACE (0.43) | OPRM1OPRK1ACEREN | |
| SCHEMBL11101521 | 0.86 | OPRK1 (0.48) | OPRM1OPRK1NPY4RNPY1RNPY2R | |
| SCHEMBL11101528 | 0.86 | OPRK1 (0.48) | OPRM1OPRK1NPY4RNPY1RNPY2R | |
| SCHEMBL29678002 | 0.86 | ACE (0.53) | OPRM1OPRK1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | claimed |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | OPRM1 3054/4885OPRK1 3862/4885ACE 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.